Selection of T1249-Resistant Human Immunodeficiency Virus Type 1 Variants

Human immunodeficiency virus type 1 (HIV-1) entry is an attractive target for therapeutic intervention. Two drugs that inhibit this process have been approved: the fusion inhibitor T20 (enfuvirtide [Fuzeon]) and, more recently, the CCR5 blocker maraviroc (Selzentry). T1249 is a second-generation fus...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Eggink, Dirk, Baldwin, Christopher E., Deng, Yiqun, Langedijk, Johannes P. M., Lu, Min, Sanders, Rogier W., Berkhout, Ben
Formato: Artigo
Idioma:Inglês
Publicado em: American Society for Microbiology (ASM) 2008
Assuntos:
Vaccines and Antiviral Agents
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC2447091/
https://ncbi.nlm.nih.gov/pubmed/18434391
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/JVI.00352-08
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados